Grants for For profit organizations other than small businesses - Science and Technology

This funding opportunity supports research and development of advanced transportation technologies, prioritizing projects that improve vehicle efficiency and battery technology while benefiting underserved communities across the U.S.

The Implementation Science for Strengthening Family Health (IS4FH) grant aims to fund organizations in implementing and evaluating interventions that enhance family health through partnerships and capacity building, with a total funding ceiling of $35 million available for innovative proposals.

This funding opportunity provides financial support to a wide range of organizations working to counter unmanned aerial system and weapons of mass destruction threats in Iraq, enhancing national security and regional stability.

This funding opportunity supports innovative breast cancer research projects that aim to address critical challenges in prevention, diagnosis, and treatment, benefiting military personnel, veterans, and the general public.

This program provides $20 million in funding to support the development of innovative recycling technologies and processes for materials used in wind turbines, targeting universities, businesses, nonprofits, and government entities.

This grant provides funding to U.S.-based nonprofit organizations and for-profit businesses to help foreign governments adopt secure American digital technologies, enhancing their cybersecurity and infrastructure capabilities.

NASA Established Program to Stimulate Competitive Research (EPSCoR) Basic Research aims to enhance research capabilities in underfunded regions by supporting innovative research initiatives that align with NASA's mission and priorities.

The City of Shreveport, through its Department of Community Development, has announced a Notice of Funding Availability (NOFA) for Affordable Rental Housing Proposals. This initiative is primarily funded by the HOME Investment Partnerships Program American Rescue Plan (HOME ARP). The core mission of this grant program is to address the critical need for affordable housing within the community by soliciting proposals from experienced agencies dedicated to developing and managing such properties. This aligns with a broader strategic priority to enhance housing stability and accessibility for vulnerable populations. The primary beneficiaries of this program are individuals and families from specific qualifying populations. These include people experiencing homelessness, those at risk of homelessness, individuals fleeing or attempting to flee domestic violence, dating violence, sexual assault, stalking, or human trafficking, and other populations where supportive services would prevent homelessness or serve those with the greatest risk of housing instability. The impact goal is to provide safe, stable, and affordable rental housing, thereby reducing homelessness and housing insecurity for these vulnerable groups. The program's priorities and focuses revolve around the production or preservation of affordable housing through new construction, rehabilitation, and property acquisition, including vacant land, specifically for HOME-ARP rental housing projects. These projects must commit to providing affordable rental housing for a minimum of 15 years. The City of Shreveport aims to fund up to three qualified entities that demonstrate extensive experience in affordable housing development, non-congregate or transitional housing operations, supportive service programs, and federal policy compliance. Expected outcomes include an increase in the number of available affordable rental housing units in Shreveport, directly benefiting the identified qualifying populations. Measurable results will likely include the number of new units constructed or rehabilitated, the number of individuals and families housed, and the duration of their housing stability. The City's strategic priority is to leverage federal funding to create a sustainable impact on housing affordability, with a theory of change that posits that by investing in experienced developers to create and preserve affordable housing, they can directly mitigate the effects of housing instability and homelessness in the community.

The CHIPS Research and Development Program (CHIPS R) aims to advance the development of semiconductor technologies and to enhance the competitiveness of the U.S. semiconductor industry. This is the first Notice of Funding Opportunity under this program. It seeks applications for new research and development (R) activities to establish and accelerate domestic capacity for advanced packaging substrates and substrate materials, a key technology for producing microelectronics systems. This NOFO seeks applications for research and development activities that will establish and accelerate domestic capacity for advanced packaging substrates and substrate materials. Through this NOFO, the NAPMP program seeks to achieve the following objectives: (1) Accelerate domestic R&D and innovation in advanced packaging materials and substrates; (2) Translate domestic materials and substrate innovation into U.S. manufacturing, such that these technologies are available to U.S. manufacturers and customers, including to significantly benefit U.S. economic and national security; (3) Support the establishment of a robust, sustainable, domestic capacity for advanced packaging materials and substrate R&D, prototyping, commercialization, and manufacturing; and (4) Promote a skilled and diverse pipeline of workers for a sustainable domestic advanced packaging industry. NAPMP plans to release subsequent NOFOs relevant to other research areas and for an Advanced Packaging Piloting Facility (APPF), where successful development efforts will be transitioned and validated for scaled transition to U.S. manufacturing. The APPF is expected to be a key facility for technology transfer to high-volume manufacturing.

This grant provides funding and technical assistance to organizations that help state, local, and Tribal governments improve their planning and permitting processes for large-scale renewable energy projects.

Orthopaedic injuries have a profound impact on military readiness and return to work/activity/duty. In the military, extremity battle wounds comprise approximately 50% of injuries reported in the Department of Defense Trauma Registry. Additionally, orthopaedic injuries and conditions that occur outside of combat (e.g., during training, leisure activities, resultant from old injuries) present one of the greatest threats to the readiness of our Service Members and military. Early stabilization, treatment, and rehabilitation of orthopaedic injuries in both civilian and military populations have led to better outcomes, particularly in the prevention of secondary complications and in minimizing morbidity. Availability of orthopaedic care and treatment as early as possible, or as close to the point of injury as possible, also minimizes limb loss and affects military readiness.Although the PRORP is interested in supporting military-focused research, research supported by the PRORP is expected to also apply to all individuals who have sustained a major orthopaedic injury.With the initiation of the Arthritis Research Program, the FY24 PRORP may not fund arthritis research; however, research that addresses conditions or health abnormalities related to arthritis is permitted provided the proposed research addresses the selected Focus Area.The PRORP CTA supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of military combat or service-related orthopaedic injuries that significantly impact unit readiness and return-to-duty/work rates. Applicants are encouraged to address how the proposed research will support patient care closer to the point of injury and/or allow patients to more quickly return to duty/work. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept trials (e.g., pilot, first-in-human, phase 0) to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations.The FY24 PRORP CTA differs from the FY24 PRORP Clinical Translational Research Award (CTRA) in that the CTRA allows for clinical research projects that may or may not include a clinical trial, whereas the CTA is restricted to clinical trials only.Funding from this award mechanism must support a clinical trial and may not be used for animal or preclinical studies. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.All applications submitted to this program announcement, regardless of the selected Focus Area, are eligible for Research Level 1.Collaborative Care Option (Research Level 2): Applications submitted to the FY24 PRORP CTA, with Focus Area Translation of Early Findings Soft Tissue Trauma, are eligible for a Collaborative Care Option (Research Level 2); refer to Section II.D.5, Funding Restrictions. The Collaborative Care Option provides additional support to encourage collaborative interdisciplinary research among physical therapists, occupational therapists, prosthetists, surgeons, and other orthopaedic care providers. The proposed research should include both surgical and rehabilitation strategies that create a cohesive project. Surgical strategies are reconstruction and repair and/or application of biologics, pharmaceuticals, and devices for the purpose of restoration of native architecture, composition, and function of traumatically injured tissues. Rehabilitative strategies are those that restore function following injury or illness, with the goal of optimal health and independence. Projects should integrate principles and approaches from surgical and rehabilitative strategies, beyond what each approach would provide by itself, with the goal of optimizing form, function, and independence for those who have sustained traumatic orthopaedic injuries. The rehabilitation strategy and the standard of care must be specified. Projects that follow patients across the continuum of care are highly encouraged. To encourage meaningful and productive multidisciplinary collaborations, projects submitted for this option must include at least one investigator with orthopaedic rehabilitation expertise and at least one clinician who specializes in orthopaedic or trauma care. A Letter of Collaboration is required from each specialist (i.e., rehabilitation expert and surgeon) who is serving as Key Personnel, excluding the Principal Investigator (PI), on the application. A clinician is defined as an individual who is credentialed (possesses the necessary degrees, licenses, and other certifications) and practicing as a care provider in a relevant capacity.If the proposed research includes a clinical trial of an investigational product to be conducted at international sites, an application to the relevant national Regulatory Agency of each host country must be submitted within 6 months of the award date.The government reserves the right to withdraw funding if an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application and/or international regulatory application is necessary but has not been submitted within 6 months of the award date.For more information, a Human Subject Resource Document is provided at https://cdmrp.health.mil/pubs/pdf/Human%20Subjects%20Resource%20Document_DEC2022.pdf.Key aspects of the PRORP CTA mechanism: Clinical Trial Start Date: The proposed clinical trial is expected to begin no later than 6 months after the award date, or 12 months after the award date for studies regulated by the Regulatory Agency. Preliminary Data Are Required: Inclusion of preliminary data relevant to the proposed clinical trial is required. Study Population: The application should demonstrate the availability of and access to a suitable patient population that will support a meaningful outcome for the study. The application should include a discussion of how accrual goals will be achieved, as well as the strategy for inclusion of women and minorities in the clinical trial appropriate to the objectives of the study. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, gender, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement. Intervention Availability: The application should demonstrate the documented availability of and access to the drug/compound, device, and/or other materials needed, as appropriate, for the proposed duration of the study. Personnel and Environment: The application should demonstrate the study teams expertise and experience in all aspects of conducting clinical trials, including appropriate statistical analysis, knowledge of U.S. Food and Drug Administration (FDA) processes (if applicable), and data management. The application should include a study coordinator(s) who will guide the clinical protocol through the local IRB of record and other federal agency regulatory approval processes, coordinate activities from all sites participating in the trial, and coordinate participant accrual. The application should show strong institutional support and, if applicable, a commitment to serve as the FDA regulatory sponsor, ensuring all sponsor responsibilities described in 21 CFR 312, Subpart D, are fulfilled. Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan, a power analysis reflecting sample size projections that will answer the objectives of the study, and a data management plan that includes use of an appropriate database to safeguard and maintain the integrity of the data. If required by a Regulatory Agency, the trial must use a 21 CFR 11-compliant database and appropriate data standards.Womens Health Research: The CDMRP encourages research on health areas and conditions that affect women uniquely, disproportionately, or differently from men, including studies analyzing sex as a biological variable. Such research should relate anticipated project findings to improvements in women's health outcomes and/or advancing knowledge for women's health.Use of DOD or VA Resources: If the proposed research involves access to DOD or VA resources or databases, the application must describe the access at the time of submission and include a plan for maintaining access as needed throughout the proposed research. Refer to Section II.D.2.b.ii, Full Application Submission Components, for detailed information. Refer to the General Application Instructions, Appendix 1, for additional information.For the purposes of this funding opportunity, Regulatory Agency refers to the FDA or any relevant international Regulatory Agency unless otherwise noted.If the proposed clinical trial involves the use of a drug that has not been approved by the relevant Regulatory Agency for the country where the research will be conducted, then submission of an IND application, or equivalent, that meets all requirements under 21 CFR 312 may be required. It is the responsibility of the applicant to provide evidence from the IRB of record or the relevant Regulatory Agency if an IND, or equivalent, is not required. If an IND, or equivalent, is required, the regulatory application must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IND, or equivalent, should be specific for the product and indication to be tested in the proposed clinical trial. For more information on IND applications specifically, the FDA has provided guidance at https://www.fda.gov/drugs/types-applications/investigational-new-drug-ind-application.If the investigational product is a device, then submission of an IDE, or equivalent, application that meets all requirements under 21 CFR 812 may be required. It is the responsibility of the applicant to provide evidence if an IDE, or equivalent, is not required. If an IDE, or equivalent, is required, the IDE application, or equivalent, must be submitted to the relevant Regulatory Agency within 6 months of the CTA award start date. The IDE, or equivalent, should be specific for the device and indication to be tested in the proposed clinical trial.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated total costs budgeted for the entire period of performance for an FY24 PRORP CTA should not exceed $2.5M (Research Level 1) or $3.25M (Research Level 2). Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $13.25M to fund approximately four Research Level 1 and one Research Level 2 CTA applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

The intent of the Breakthrough Award is to support promising research that has high potential to lead to or make breakthroughs in breast cancer. The critical components of this award mechanism are:Impact: Research supported by the Breakthrough Award will have the potential for a major impact and accelerate progress toward ending breast cancer. The impact may be near-term or long-term but must move beyond a minor advancement and have the potential to lead to a fundamentally new approach that is significantly more effective than interventions already approved or in clinical development. Applications are expected to identify the breast cancer patients or at-risk individuals who would ultimately benefit from the proposed research.Research Scope: The Breakthrough Award is structured with four different funding levels. The levels are designed to support major (but not all) stages of research that will lead to clinical application. Each level has a defined research scope. It is the responsibility of the Principal Investigator (PI) to select the level that aligns with the scope of the proposed research. The funding level should be selected based on the research scope defined in the program announcement, and not on the amount of the budget.The current program announcement discusses the Breakthrough Award Levels 1 and 2. Funding Levels 3 and 4 are available under other program announcements (HT942524BCRPBTA3 and HT942524BCRPBTA4, respectively). The PI is strongly encouraged to review the research scope defined under each funding level as described in the corresponding Breakthrough Award program announcement before submitting the pre-application. An application that does not meet the intent of the funding level selected will not be recommended for funding, even if it might meet the intent of a different funding level.The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under the current program announcement: Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are not required. Proof of concept is the anticipated outcome. Funding Level 2: Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within thebreast cancer landscape. Funding Level 2: Population Science and Prevention Studies: Population Science and Prevention Studies should involve investigations into why certain human patient populations differ in cancer risk or clinical prognosis. The studies should focus on the analysis of human data and biospecimens. Research should be already supported by substantial preliminary or published data and strongly validate clinical translation in a well-defined context within the breast cancer landscape. With compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance.Partnering PI Option: The Breakthrough Award encourages applications that include meaningful and productive partnerships between investigators. The Partnering PI Option is structured to accommodate two PIs. One PI will be identified as the Initiating PI and will be responsible for the majority of the administrative tasks associated with application submission. The other PI will be identified as a Partnering PI. Both PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW), and other required components. The PIs may have expertise in similar or disparate scientific disciplines, but each PI is expected to bring distinct contributions to the application. The application should clearly demonstrate that both PIs have equal intellectual input into the design of the project and will devote similar and appropriate levels of effort to the conduct of the project. It is expected that funding will be balanced between both PIs unless appropriately justified. New partnerships are encouraged, but not required. The application is expected to describe how the PIs unique expertise combined as a partnership will better address the research question, how the unique expertise that each individual brings to the application is critical for the research strategy and completion of the SOW, and why the work should be done together rather than through separate efforts. To meet the intent of the Partnering PI Option, applicants are discouraged from being named as a Partnering PI on multiple Breakthrough Award Levels 1 and 2 applications unless they are clearly unique, meaningful partnerships addressing distinct research questions. Applications in which a mentor and their current postdoctoral fellow or junior investigator are named as Initiating and Partnering PIs do not meet the intent of the Partnering PI Option. Applications where one PI is providing samples, animal models, or investigational agents while the other PI is conducting most, or all of the experiments and analyses, do not meet the intent of the Partnering PI Option. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Initiating and Partnering PIs, refer to Section II.D.2, Content and Form of the Application Submission.Personnel: Applications are expected to include an appropriate and robust research team with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the project.Research involving human subjects and research involving human anatomical substances and data is permitted; however, clinical trials are not allowed under this funding opportunity.Applications seeking support for a clinical trial may be submitted to the FY24 BCRP Breakthrough Award Level 3 and Level 4 program announcements (HT942524BCRPBTA3 and HT942524BCRPBTA4, respectively).A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, CDMRP encourages applicants to review the recommendations (https://health.mil/Reference-Center/Congressional-Testimonies/2018/05/03/Metastatic-Cancer-Research) and submit research ideas to address these recommendations provided they are within the limitations of this funding opportunity and fit within the FY24 BCRP priorities.Innovative research involving nuclear medicine and related techniques to support early diagnosis, more effective treatment, and improved health outcomes of active-duty Service Members and their Families is encouraged. Such research could improve diagnostic and targeted treatment capabilities through noninvasive techniques and may drive the development of precision imaging and advanced targeted therapies.The proposed research must be relevant to active-duty Service Members, Veterans, military beneficiaries, and/or the American public. Collaborations between researchers at military or Veteran institutions and non-military institutions are strongly encouraged. These relationships can leverage knowledge, infrastructure, and access to unique clinical populations that the partners bring to the research effort, ultimately advancing cancer research that is of significance to the Warfighter, military Families, and the American public.Clinical trials are not allowed. A clinical trial is defined in the Code of Federal Regulations, Title 45, Part 46.102 (45 CFR 46.102) as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research encompasses research with human data, human specimens, and/or interaction with human subjects. Clinical research is observational in nature and includes:(1) Research conducted with human subjects and/or material of human origin such as data, specimens, and cognitive phenomena for which an investigator (or co-investigator) does not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention. Research meeting this definition may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies.(2) Epidemiologic and behavioral studies that do not seek to assess the safety, effectiveness, and/or efficacy outcomes of an intervention.(3) Outcomes research and health services research that do not fit under the definition of clinical trial.Excluded from the definition of clinical research are in vitro studies that utilize human data or specimens that cannot be linked to a living individual and meet the requirements for exemption under 46.104(d)(4) of the Common Rule.The funding instrument for awards made under the program announcement will be grants (31 USC 6304).The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Funding Level 1 should not exceed $450,000 for applications with a single PI or $750,000 if applying under the Partnering PI Option.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Level 2 should not exceed $1.0M for applications with a single PI or $1.5M if applying under the Partnering PI Option.The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Breakthrough Award Funding Level 2, Population Science and Prevention Studies, should not exceed $1.5M for applications with a single PI or $2.0M if applying under the Partnering PI Option. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.Awards supported with FY24 funds will be made no later than September 30, 2025.The CDMRP expects to allot approximately $20.9M to fund approximately 14 Breakthrough Award Levels 1 and 2 applications. Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY24 funding opportunity will be funded with FY24 funds, which will expire for use on September 30, 2030.

This funding opportunity provides additional financial support to active health services research projects facing unforeseen costs, helping researchers continue their work effectively.

The Opelousas Downtown Development District (ODDD), with support from the City of Opelousas and Opelousas Main Street (OMS), is launching the fifth round of funding for its Building Improvement Grant (BIG) program. This program is a grant/reimbursement initiative designed to empower property and business owners in rehabilitating commercial buildings. The overarching mission alignment for this program is to create a positive visual impact within the city, stimulate private investment, and diligently preserve Opelousas' historic identity and cultural assets. The primary beneficiaries of this grant program are property and business owners within the Opelousas Downtown Development District who own commercial buildings. The core impact goals are to foster economic development through private investment, enhance the aesthetic appeal of the downtown area, and ensure the safeguarding of the city's rich historical and cultural heritage. The program directly supports the revitalization of commercial spaces, which, in turn, contributes to a more vibrant and economically robust downtown. The program's priorities and focuses are clearly on tangible and permanent building improvements. Eligible uses of funds are comprehensive, including restoration and renovation of buildings, installation of awnings (without signage), brick cleaning or re-pointing, accent lighting, removal of deteriorating or inappropriate materials visible from the street, and restoration of windows, doors, and original exterior/interior architectural features. Additionally, interior work related to ceiling repair, electrical, and plumbing is covered, as well as work on roofs, cornices, gutters, downspouts, and the cleaning, preparation, and painting of walls and trim. These priorities are aimed at holistic improvement of commercial properties. The expected outcomes include a noticeable improvement in the visual appeal of downtown Opelousas, an increase in private investment in commercial properties, and the successful preservation of historic buildings. While not explicitly stated as "measurable results" in the traditional sense, the program's structure and goals imply that the number of rehabilitated buildings, the amount of private investment stimulated, and the visible improvements in the downtown area would serve as key indicators of success. The program offers a total of $200,000 in grant funds, with a maximum application amount of $10,000 per project, providing a clear framework for financial allocation and impact tracking.

This funding opportunity is designed to support researchers and organizations developing advanced communication and networking technologies to enhance the operational capabilities of the Navy and Marine Corps.

The OCRP Investigator-Initiated Research Award is intended to support high-impact research that addresses a critical need and has the potential to make an important contribution to ovarian cancer or patient/survivor care. Research projects may focus on any phase of research, from basic laboratory research through translational research, excluding clinical trials. The application must demonstrate logical reasoning and a sound scientific rationale established through a critical review and analysis of the literature for the application to be competitive. Applications must include preliminary data that are relevant to ovarian cancer and support the proposed research project. These data may be unpublished or from the published literature.

The Toolbox grant, offered by the Live Music Society, is specifically designed to support venue owners in implementing one-time, practical projects that enhance their spaces for performers, staff, and visitors. This grant directly aligns with the foundation's mission to elevate the live music experience by addressing essential, practical needs of music venues. Unlike the Music in Action grant, which focuses on broader audience development and community building, the Toolbox grant is strategically focused on tangible venue improvements. The primary beneficiaries of the Toolbox grant are live music venue owners in the United States and its territories who operate venues with a legal capacity of 50-300 and present a minimum of 50 music performances annually. The impact goals are to empower venues to improve safety and comfort, modernize operations through innovative technology, address practical challenges with expert consultants, and invest in staff training and education. The Live Music Society's theory of change is that by supporting these specific, practical improvements, venues can significantly enhance the overall live music experience for musicians, staff, and audiences. The priorities and focuses of the Toolbox grant are clear: supporting practical projects that lead to concrete improvements. This includes initiatives like enhancing safety and comfort, incorporating innovative technology, engaging consultants for specialized challenges (e.g., acoustics, ticketing, fundraising, branding), and providing staff training and education. While examples are provided, the funding is not limited to these, encouraging venues to propose any practical challenge they believe qualifies for support, thereby fostering a responsive and needs-driven approach. Expected outcomes include more comfortable and safer environments for all venue occupants, more efficient and modern operations, and improved capacity through specialized expertise and staff development. Measurable results could include the successful completion of specific projects, enhanced venue features (e.g., new sound systems, improved accessibility), and demonstrable improvements in staff capabilities or operational efficiency. Applicants can request up to $10,000 per application, with projects taking place between December 1, 2024, and May 31, 2025, ensuring a focused and timely impact on the recipient venues.

This funding opportunity provides financial support for researchers at domestic institutions to study atmospheric processes using data from the Department of Energy's ARM facility, with a focus on improving climate models and understanding critical environmental factors.

Through the support of the Centers for Disease Control and Prevention (CDC), the Urban Indian Health Institute (UIHI) launched a nationwide initiative to not only enhance evidence-based culturally rigorous chronic disease prevention programs but also to enhance public health infrastructure among urban Indian organizations. This initiative aligns with UIHI's mission to serve urban Indian communities by promoting health and preventing chronic diseases through culturally appropriate approaches. The grant program, called Sweetgrass funds, focuses on Indigenous approaches to preventing chronic diseases. The target beneficiaries of this grant are Urban Indian Organizations (UIOs) as defined by the Indian Health Service (Title V programs), members of the National Urban Indian Family Coalition (NUIFC), and not-for-profit urban Indian organizations whose leadership and board are majority urban Indian, and whose mission is to provide public health services to urban Indians. The impact goals are to address and prevent chronic diseases such as obesity, commercial tobacco use, Type 2 Diabetes, and heart disease and stroke within these communities. The program encourages the use of AI/AN traditional, cultural, and regional knowledge in developing and implementing chronic disease education, prevention, and management initiatives. The program prioritizes expanding previous projects related to obesity prevention, commercial tobacco use prevention and cessation promotion, Type 2 Diabetes prevention, and heart disease and stroke prevention. Specific approaches include using cultural or regional adaptations of chronic disease prevention education program components, reclaiming traditional knowledge of nutrition and first foods, promoting access to physical activity and lifestyle modifications, engaging Native youth and elders, addressing perceptions and beliefs, promoting traditional values, and emphasizing community-driven planning for chronic disease prevention and control, such as community needs assessments. Expected outcomes include enhanced evidence-based and culturally rigorous chronic disease prevention programs, improved public health infrastructure among urban Indian organizations, and a reduction in the prevalence of chronic diseases within urban Indian communities. Applicants are required to participate in performance measurement, evaluation activities, and a chronic disease community of practice, which includes annual webinar-based trainings and optional technical assistance services, all coordinated by UIHI. This structured approach ensures measurable results and continuous improvement in addressing chronic diseases with a broad reach across the United States.

The DOD Pancreatic Cancer, Focused Pilot Award is a grant that supports innovative research projects aimed at improving the quality of life for pancreatic cancer patients, with a focus on areas such as healthcare access, mental health, psycho-social issues, nutrition, education, and symptom management.